title: Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus.
abstract: The consumption of foods containing probiotic and prebiotic ingredients is growing consistently every year, and in view of the limited number of studies investigating their effect in the elderly.
  
  
  
  The objective of this study was to evaluate the effect of the consumption of a symbiotic shake containing Lactobacillus acidophilus, Bifidobacterium bifidum and fructooligosaccharides on glycemia and cholesterol levels in elderly people.
  
  
  
  A randomized, double-blind, placebo-controlled study was conducted on twenty volunteers (ten for placebo group and ten for symbiotic group), aged 50 to 60 years. The criteria for inclusion in the study were: total cholesterol > 200 mg/dL; triglycerides > 200 mg/dL and glycemia > 110 mg/dL. Over a total test period of 30 days, 10 individuals (the symbiotic group) consumed a daily dose of 200 mL of a symbiotic shake containing 10(8) UFC/mL Lactobacillus acidophilus, 10(8) UFC/mL Bifidobacterium bifidum and 2 g oligofructose, while 10 other volunteers (the placebo group) drank daily the same amount of a shake that did not contain any symbiotic bacteria. Blood samples were collected 15 days prior to the start of the experiment and at 10-day intervals after the beginning of the shake intake. The standard lipid profile (total cholesterol, triglycerides and HDL cholesterol) and glycemia, or blood sugar levels, were evaluated by an enzyme colorimetric assay.
  
  
  
  The results of the symbiotic group showed a non-significant reduction (P > 0.05) in total cholesterol and triglycerides, a significant increase (P < 0.05) in HDL cholesterol and a significant reduction (P < 0.05) in fasting glycemia. No significant changes were observed in the placebo group.
  
  
  
  The consumption of symbiotic shake resulted in a significant increase in HDL and a significant decrease of glycemia.
authors.affiliation: Department of Food & Nutrition, School of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil.
authors.forename: Camila
authors.initials: C
authors.lastname: Moroti
authors.forename: Loyanne Francine
authors.initials: LF
authors.lastname: Souza Magri
authors.forename: Marcela
authors.initials: M
authors.lastname: de Rezende Costa
authors.forename: Daniela C U
authors.initials: DC
authors.lastname: Cavallini
authors.forename: Katia
authors.initials: K
authors.lastname: Sivieri
mesh_terms: D000284:Administration, Oral; D001644:Bifidobacterium; D001786:Blood Glucose; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy*; D015228:Hypertriglyceridemia / Q000150:complications / Q000628:therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007779:Lactobacillus acidophilus; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D013559:Symbiosis; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D009844:Oligosaccharides; C116580:fructooligosaccharide; D002784:Cholesterol